The total return over the past 12 months is +100.16% vs. +16.94% for the S&P 500. So far it's up +147.30% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +100.16% | +11.35% | (46.86%) | (2.31%) | N/A | N/A |
| Total Return CAGR | +100.16% | +11.35% | (46.86%) | (2.31%) | N/A | N/A |
| Revenue CAGR | (23.36%) | (62.09%) | (32.98%) | +3.85% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Fate Therapeutics, Inc. (FATE)
| Year | Start price | End price | FATE Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $0.98 | $2.43 | +147.30% | +14.51% | +132.79% |
| 2025 | $1.65 | $0.98 | (40.45%) | +17.72% | (58.17%) |
| 2024 | $3.74 | $1.65 | (55.88%) | +24.89% | (80.77%) |
| 2023 | $10.09 | $3.74 | (62.93%) | +26.19% | (89.12%) |
| 2022 | $58.51 | $10.09 | (82.76%) | (18.17%) | (64.59%) |
| 2021 | $90.93 | $58.51 | (35.65%) | +28.74% | (64.39%) |
| 2020 | $19.57 | $90.93 | +364.64% | +18.37% | +346.27% |
| 2019 | $12.83 | $19.57 | +52.53% | +31.22% | +21.31% |
| 2018 | $6.11 | $12.83 | +109.98% | (4.56%) | +114.54% |
| 2017 | $2.51 | $6.11 | +143.43% | +21.70% | +121.73% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
